| Literature DB >> 23382907 |
Yan Yang1, Yan Wang, Zhong-wei Shi, Ding-liang Zhu, Ping-jin Gao.
Abstract
OBJECTIVES: To evaluate the association of left ventricular (LV) diastolic function and N-terminal pro-brain natriuretic peptide (NT-proBNP) with renal function in essential hypertension.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23382907 PMCID: PMC3557266 DOI: 10.1371/journal.pone.0054513
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics.
| Variables | Group 1 E/E′≤10(n = 48) | Group 210<E/E′≤15(n = 109) | Group 3E/E′>15 (n = 50) | P value |
| Age (years) | 47.8±15.5 | 54.9±11.8 | 64.4±12.4 | <0.0001 |
| Male, n (%) | 31 (65) | 65 (60) | 25(50) | 0.06 |
| Body mass index (kg/m2) | 24.6±3.7 | 25.9±3.3 | 24.9±3.2 | 0.04 |
| 24-h mean SBP (mmHg) | 126±13 | 130±16 | 135±16 | 0.03 |
| 24-h mean DBP (mmHg) | 80±10 | 81±11 | 75±9 | 0.004 |
| 24-h mean PP (mmHg) | 46±8 | 49±12 | 60±13 | <0.0001 |
| 24-h mean HR (bpm) | 74±9 | 72±9 | 67±7 | 0.002 |
| Diabetes, n (%) | 9 (19) | 21 (19) | 12 (24) | 0.75 |
| Serum TC (mg/dl) | 189±39 | 182±43 | 186±31 | 0.75 |
| Serum TG (mg/dl) | 168±132 | 204±150 | 177±177 | 0.45 |
| Fasting glucose (mg/dl) | 97±16 | 99±20 | 99±31 | 0.86 |
| lg NT-proBNP | 1.3±0.5 | 1.5±0.5 | 2.2±0.5 | <0.0001 |
| hs-CRP (mg/l) | 2.5±4.0 | 2.8±4.0 | 4.3±8.4 | 0.23 |
| BUN (mg/dl) | 6.6±1.7 | 7.3±2.1 | 8.4±5.2 | 0.018 |
| Serum creatinine (mg/dl) | 0.88±0.14 | 0.95±0.28 | 1.03±0.40 | 0.052 |
| eGFR(ml/min/1.73 m2) | 114±17 | 104±26 | 97±27 | 0.0002 |
| GFR(ml/min/1.73 m2) | 88±18 | 82±21 | 65±20 | <0.0001 |
| lg UACR | 1.03±0.39 | 1.19±0.47 | 1.62±0.70 | <0.0001 |
| Echocardiographic parameter | ||||
| LVMI (g/m2) | 100±19 | 111±24 | 134±37 | <0.0001 |
| LV Shortening fraction (%) | 37±4 | 37±5 | 37±4 | 0.97 |
| LAVI (ml/m2) | 20.9±4.6 | 22.4±3.9 | 26.6±5.2 | <0.0001 |
| E/A | 1.08±0.35 | 1.00±0.33 | 0.97±0.34 | 0.68 |
| Deceleration time (ms) | 230±50 | 221±49 | 239±57 | 0.12 |
| IVRT (ms) | 102±22 | 107±26 | 124±39 | 0.0003 |
| Anti-hypertensive drugs | ||||
| ACE-I, n (%) | 13 (27) | 30 (28) | 17 (34) | 0.67 |
| ARB, n (%) | 16 (33) | 46 (42) | 20 (40) | 0.58 |
| CCB, n (%) | 36 (75) | 82 (75) | 38 (76) | 0.99 |
| Beta-Blocker, n (%) | 12 (25) | 30 (28) | 21 (42) | 0.12 |
| Diuretic, n (%) | 8 (17) | 27 (25) | 16 (32) | 0.21 |
SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; HR: heart rate; TC: total cholesterol; TG: triglycerides; hs-CRP: high sensitivity C-creative protein; UACR: Urinary albumin creatinine ratio; ACE-I: medication with angiotensin-converting enzyme (ACE) inhibitor; ARB: medication with angiotensin receptor blocker; CCB: medication with calcium channel blocker; LVMI: left ventricular mass index; LAVI: left atrial volume index; IVRT: isovolumic relaxation time.
Significant difference with group 1.
Significant difference with group 2.
Univariate and multiple stepwise linear model of GFR.
| Variables | Univariate | Stepwise | ||
| r | P | Standardized β± SE | P | |
| Age | −0.431 | <0.0001 | −0.30±0.22 | 0.001 |
| Gender | 0.217 | 0.002 | 0.22±3.24 | 0.003 |
| Body mass index (kg/m2) | 0.103 | 0.15 | ||
| Use of ACE-I or ARB drugs | 0.052 | 0.29 | ||
| 24-h mean SBP (mmHg) | −0.155 | 0.043 | ||
| 24-h mean HR (bpm) | 0.255 | 0.001 | ||
| Diabetes | −0.045 | 0.54 | ||
| LVMI (g/m2) | −0.325 | <0.0001 | ||
| LAVI (ml/m2) | −0.305 | <0.0001 | ||
| E/A | 0.216 | 0.003 | ||
| Deceleration time (ms) | −0.198 | 0.006 | ||
| IVRT (ms) | −0.284 | <0.0001 | ||
| E/E′ | −0.374 | <0.0001 | −0.21±0.53 | 0.03 |
| lg NT-proBNP | −0.463 | <0.0001 | −0.29±3.18 | 0.001 |
| lg UACR | −0.347 | <0.0001 | −0.20±3.13 | 0.01 |
Abbreviations as in Table 1.
Figure 1The relationship between GFR or UACR and E/E′ or NT-proBNP.
GFR was significantly correlated with E/E′ and log-transformed plasma NT-proBNP, the correlation coefficient was −0.374 and −0.463 respectively (P<0.0001). Log-transformed UACR was also significantly correlated with E/E′ and log-transformed plasma NT-proBNP, the correlation coefficient was 0.323 and 0.382 respectively (P<0.0001).
Univariate and multiple stepwise linear model of eGFR.
| Variables | Univariate | Stepwise | ||
| r | P | Standardized β± SE | P | |
| Age | −0.373 | <0.0001 | −0.33±0.13 | <0.0001 |
| Gender | 0.190 | 0.007 | 0.18±3.62 | 0.02 |
| Body mass index (kg/m2) | 0.018 | 0.80 | – | – |
| Use of ACE-I or ARB drugs | −0.059 | 0.41 | – | – |
| 24-h mean SBP (mmHg) | −0.134 | 0.07 | – | – |
| 24-h mean HR (bpm) | 0.250 | 0.001 | – | – |
| Diabetes | −0.059 | 0.40 | – | – |
| LVMI (g/m2) | −0.383 | <0.0001 | – | – |
| LAVI (ml/m2) | −0.305 | <0.0001 | – | – |
| E/A | −0.133 | 0.06 | – | – |
| Deceleration time (ms) | −0.207 | 0.003 | – | – |
| IVRT (ms) | −0.335 | <0.0001 | −0.21±61.30 | 0.02 |
| E/E′ | −0.299 | <0.0001 | – | – |
| lg NT-proBNP | −0.331 | <0.0001 | – | – |
| lg UACR | −0.341 | <0.0001 | −0.22±3.36 | 0.005 |
Abbreviations as in Table 1.
Figure 2Association of E/E′ and NT-proBNP with GFR.
(white box, lgNT-proBNP<1.65; shaded box, lgNT-proBNP>1.65) * P<0.01 vs lgNT-proBNP<1.65 and E/E′<15, # P<0.01 vs lgNT-proBNP>1.65 and E/E′<15, $ P<0.05 vs lgNT-proBNP<1.65 and E/E′>15.
Associations of E/E′ with Stage 3 CKD (defined as 30
| Model 1 | Model 2 | Model 3 | ||||
| ORs(95% CI) | P | ORs(95% CI) | P | ORs(95% CI) | P | |
| E/E′≤10 | 1 [reference] | 1 [reference] | 1 [reference] | |||
| 10<E/E′≤15 | 1.57[0.59–4.20] | 0.36 | 1.64[0.58–4.59] | 0.34 | 2.80[0.82–9.60] | 0.09 |
| E/E′>15 | 6.46[2.33–19.91] | 0.0003 | 6.01[1.95–18.45] | 0.002 | 8.31[2.00–34.56] | 0.004 |
| P for trend | <0.0001 | 0.0006 | 0.002 | |||
Model 1: unadjusted.
Model 2: adjusted for age, gender, and body mass index.
Model 3: adjusted for all the potential confounding factors including age, gender, body mass index, prevalence of diabetes, use of ACE-I or ARB drugs, 24-h mean systolic blood pressure, LVMI, LAVI, E/A, deceleration time, IVRT, lgNT-proBNP and lgUACR.
Abbreviations as in Table 1.
Associations of E/E′ with Stage 3 CKD (defined as 30
| Model 1 | Model 2 | Model 3 | ||||
| ORs(95% CI) | P | ORs(95% CI) | P | ORs(95% CI) | P | |
| E/E′≤10 | 1 [reference] | 1 [reference] | 1 [reference] | |||
| 10<E/E′≤15 | 2.07[0.43–9.96] | 0.36 | 2.14[0.42–10.92] | 0.35 | 2.76[0.508–15.08] | 0.66 |
| E/E′>15 | 3.744[0.74–19.02] | 0.11 | 2.59[0.45–14.95] | 0.28 | 3.28[0.54–19.78] | 0.23 |
| P for trend | 0.08 | 0.31 | 0.21 | |||
Model 1: unadjusted.
Model 2: adjusted for age, gender, and body mass index.
Model 3: adjusted for all the potential confounding factors including age, gender, prevalence of diabetes, use of ACE-I or ARB drugs, body mass index, 24-h mean systolic blood pressure, LVMI, LAVI, E/A, deceleration time, IVRT, lgNT-proBNP and lgUACR.
Abbreviations as in Table 1.